玻尿酸又稱透明質酸，由雙糖作為基本結構而形成的糖胺聚糖，在人體裡可發現其存在於真皮層中幫助皮膚鎖住水分使肌膚保有彈性，然而隨著時間增加位於人體裡的玻尿酸會逐漸減少而產生皺紋。目前玻尿酸被醫學美容廣泛運用於皮下填充物上，其副作用低、方便取得及排斥現象少等特性深受大眾喜愛，另一方面也常被當作潤滑劑作用於關節炎治療，產品價值相當高，但其存在人體裡經一段時間會被玻尿酸酶分解代謝掉，若想要繼續維持玻尿酸所帶來之效果則必須重覆施打。
本研究目的為以產業生產的碎金/銀薄膜與玻尿酸做結合改善玻尿酸在人體內的降解特性。金擁有相當高的生物相容性不會被人體所排斥，當碎金箔伴隨玻尿酸植入人體皮下，刺激皮膚增生纖維母細胞及膠原蛋白，即使在玻尿酸被降解代謝後仍然可以達到原先的填充效果，進而增加使用的時效性，而銀的離子以及化合物對某些細菌、病毒、藻類以及真菌顯現出毒性，但對人體卻幾乎是完全無害的。銀的這種殺菌效應使得它在活體外就能夠將生物殺死。因此我們將京華堂 Vita Gold 提供之 PVD-金及銀混合現有皮下填充材玻尿酸進行試驗，開發新的皮下填充材料，以期能改善現階段皮下填充物在皮下填充時間過短的問題，並觀察碎金/銀箔在動物皮下所產生的反應，若能有效減緩玻尿酸降解且並未造成皮下組織產生不良反應，未來將有效改善玻尿酸於人體的應用並降低免疫反應的機率。
京華堂實業股份有限公司生產的純度9999的碎金/銀箔已完成過篩，經量測後粒徑皆小於38 µm；玻尿酸的平均電為約介於-16.62 ±19.89mV，碎金/銀薄膜的平均電位則落於-72.28 ±5.06mV與-71.92 ±9.71mV，將玻尿酸與為金/銀薄膜依比例混合後所得倒的電位分別為-27.57 ±14.22mV(HA：Au=10：1)與-20.92 ±7.48mV (HA：Ag=10：1)，加了玻尿酸後的碎金/銀薄膜電位隨之變大；玻尿酸的黏滯度受流變儀的轉速(剪力，Shear Force)所影響，當轉速越高，所受Shear Force越大，所測得的黏滯度越小，除了轉速大小，也受溫度變化影響，當溫度升高，黏滯度會逐漸下降。

A natural substance, hyaluronic acid (HA), is an anionic, nonsulfated glycosaminoglycan found in the human dermis. Our skin ability to produce HA declines with age, which can lead to increased dryness, fine lines, wrinkles and sagging. Currently, HA is used as a dermal filler in cosmetic surgery and is used to treat knee pain caused by osteoarthritis. There are very few side effects of using hyaluronic acid. However, natural HA can be rapidly degraded by enzymes and radicals existing in the human body. The effect of the treatment for dermal defects such as wrinkles via the injection of free HA into injections skin only lasts for less than a week.
Cross-linked fillers consist of a homogeneous mixture of high- and low-molecularweight HA, making their application easier. This proposal is mainly to assess the efficiency of a safer and longer lasting filler, cross-linked filler containing gold particles, for the proliferation of subcutaneous collagen fiber. To estimate the feasibility of the cross-linked filler containing gold particles provided by Gold NanoTech Inc. (GNT), in vivo small animal study would be performed to evaluate the optimal condition of cross-linked filler containing gold particles.
The crushed gold/silver flake of 9999 purity produced by Gold NanoTech, Inc. has been sieved, and the particle size is less than 38 μm after measurement. The average electricity of hyaluronic acid is about -16.62±19.89 mV. The average potential of gold/silver flake falls to -72.28±5.06 mV and -71.92±9.71 mV. The potential of the hyaluronic acid mixed with the gold/silver flake is -27.57±14.22 mV (HA:Au = 10:1) and -20.92±7.48 mV (HA:Ag = 10:1). Therefore,the potential of the gold/silver flake after adding hyaluronic acid becomes larger. The viscosity of hyaluronic acid is affected by the rheometer rotation speed (shear force). As the higher speed, the measured viscosity become smaller if the shear force get laeger. In addition to the speed, it is also affected by the changing of temperature. When the temprature rises, the viscosity will gradually decrease.

[1] R. R. Wickett and M. O. Visscher, "Structure and function of the epidermal barrier," American Journal of Infection Control, vol. 34, no. 10, pp. S98-S110, 2006.
[2] Boundless. (2016). Structure of the Skin: Epidermid.
[3] K. Suehiro et al., "Skin and subcutaneous tissue strain in legs with lymphedema and lipodermatosclerosis," Ultrasound Med Biol, vol. 41, no. 6, pp. 1577-83, Jun 2015.
[4] A. L. Berlin, M. Hussain, and D. J. Goldberg, "Calcium hydroxylapatite filler for facial rejuvenation: a histologic and immunohistochemical analysis," Dermatol Surg, vol. 34 Suppl 1, pp. S64-7, Jun 2008.
[5] Y. Y. Loghem JV, Philip Werschler WJ., "Calcium hydroxylapatite: over a decade of clinical experience.," Clin Aesthet Dermatol, vol. 8, pp. 38-49, 2015.
[6] A. Josefsson et al., "Prostate cancer increases hyaluronan in surrounding nonmalignant stroma, and this response is associated with tumor growth and an unfavorable outcome," Am J Pathol, vol. 179, no. 4, pp. 1961-8, Oct 2011.
[7] P. G. Gritsenko, O. Ilina, and P. Friedl, "Interstitial guidance of cancer invasion," J Pathol, vol. 226, no. 2, pp. 185-99, Jan 2012.
[8] F. G. Csoka AB, Stern R., " The six hyaluronidase-like genes in the human and mouse genomes.," Matrix Biol., vol. 20, pp. 499-508, 2001.
[9] R. Stern, "Devising a pathway for hyaluronan catabolism: are we there yet?," Glycobiology, vol. 13, no. 12, pp. 105R-115R, Dec 2003.
[10] R. Stern, "Hyaluronan catabolism: a new metabolic pathway," Eur J Cell Biol, vol. 83, no. 7, pp. 317-25, Aug 2004.
[11] L. T. Fraser JR, Laurent UB, "Hyaluronan: its nature, distribution, functions and turnover," Intern. Med, vol. 242, pp. 27–33, 1997.
[12] L. Jadin, L. H. Bookbinder, and G. I. Frost, "A comprehensive model of hyaluronan turnover in the mouse," Matrix Biol, vol. 31, no. 2, pp. 81-9, Mar 2012.
[13] B. P. Å. k. C. Å gerup B, "Non-animal stabilized hyaluronic acid: a new formulation for the treatment of osteoarthritis," BioDrugs, vol. 19, pp. 23–30, 2005.
[14] K. Edsman et al., "Intra-articular Duration of Durolane after Single Injection into the Rabbit Knee," Cartilage, vol. 2, no. 4, pp. 384-8, Oct 2011.
[15] A. La Gatta, C. Schiraldi, A. Papa, and M. De Rosa, "Comparative analysis of commercial dermal fillers based on crosslinked hyaluronan: Physical characterization and in vitro enzymatic degradation," Polymer Degradation and Stability, vol. 96, no. 4, pp. 630-636, 2011.
[16] K. Edsman, L. I. Nord, A. Ohrlund, H. Larkner, and A. H. Kenne, "Gel properties of hyaluronic acid dermal fillers," Dermatol Surg, vol. 38, no. 7 Pt 2, pp. 1170-9, Jul 2012.
[17] A. Tezel and G. H. Fredrickson, "The science of hyaluronic acid dermal fillers," J Cosmet Laser Ther, vol. 10, no. 1, pp. 35-42, Mar 2008.
[18] J. Newman, "Review of soft tissue augmentation in the face," Clin Cosmet Investig Dermatol., pp. 141-150, 2009.
[19] G. E. Linesnmayer TF, Gorden MK, Marchant JK, Hayashi M & Fitch JM., "Extracellylar materices of developing chick retina and cornea. Localization of mRNAs for collagen types II and IX by in situ hybridization. Invest ophthalmol visual.," sci, vol. 31, pp. 1271-1276, 1990.
[20] "Genetics Home Reference.," U.S. National Library of Medicine, 2014-05-05 2014.
[21] I. A. Darby and T. D. Hewitson, "Fibroblast Differentiation in Wound Healing and Fibrosis," (International Review of Cytology, 2007, pp. 143-179.
[22] 李和、李繼承, 《組織學與胚胎學》第三版. 人民衛生出版社, 2015.
[23] P. W. Ross M, Histology: A Text and Atlas 6th. Lippincott Williams & Wilkins., 2011.
[24] Dr.Stanley. (2014). 微整注射填充物的比較.
[25] 林煜庭, "玻尿酸皮膚填補物技術性文件考量," RegMed2011.
[26] S. S. Johl, & Burgett, R. A. , "Dermal filler agents:a practical review," Current Opinion in Ophthalmology, vol. 17, pp. 471-479, 2006.
[27] 陳樹人, "玻尿酸專題報導," 應用生物科技研究室.
[28] J. W. Kuo, "practical-aspects-of-hyaluronan-based-medical-prod," CRC Press, pp. 79-93, 2006.
[29] T. Gower. (2019). Hyaluronic Acid Injections for Osteoarthritis.
[30] J. P. Rutjes AW, da Costa BR, Trelle S, Nüesch E, Reichenbach S, "Viscosupplementation for osteoarthritis of the knee," Ann. Intern. Med., vol. 157, no. 3, pp. 180–91, 2012.
[31] (2019). Hylira gel: Indications, Side Effects, Warnings. Available: https://www.drugs.com/cdi/hylira.html
[32] A. D. Pucker, S. M. Ng, and J. J. Nichols, "Over the counter (OTC) artificial tear drops for dry eye syndrome," Cochrane Database Syst Rev, vol. 2, p. CD009729, Feb 23 2016.
[33] A. A. Shaharudin, Z., "Effectiveness of hyaluronic acid and its derivatives on chronic wounds: a systematic review," Journal of Wound Care, vol. 25, no. 10, pp. 585–592.
[34] A. G. Chen WYJ, "Functions of hyaluronan in wound repair," Wound Repair Regen, vol. 7, no. 2, pp. 79–89, 1999.
[35] S. Fernandez-Cossio and M. T. Castano-Oreja, "Biocompatibility of two novel dermal fillers: histological evaluation of implants of a hyaluronic acid filler and a polyacrylamide filler," Plast Reconstr Surg, vol. 117, no. 6, pp. 1789-96, May 2006.
[36] PVD加工的GNT Gold和膠體金. Available: http://www.gnt.com.tw/english/explore/detail.php?pid=5
[37] 物理氣相沉積介紹.
[38] Anton Paar Rheometer MCR102. Available: http://www.labwrench.com/?equipment.view/equipmentNo/27518/Anton-Paar/Rheometer-MCR-102--302--502/